ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4325)	6/23/2016 9:55:19 PM
From: jaybe	of 4474

Maybe they tried and were met with a different form of resistance...in HB. In any case this research corroborates FGFR/FRS2 and stat3 as promoters of MEK resistance in KRASm cancers, and ponatinib's ability to inhibit both, synergistically. This is likely an outcome of the first phase of the Lung Cancer Dream Team, supported by ACS and SU2C, as a few authors are members, announced in 2015. "First, the researchers will identify the most effective therapies for targeting KRAS and other related biological pathways. Second, they will develop approaches to exploit the immune system for the treatment of KRAS-mutant lung cancers. Third, they will integrate targeted therapies with immunotherapies as a novel combined approach to treatment of KRAS-mutant lung cancer." standup2cancer.org cancer.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next